MED11

Across TCGA pan-cancer cohorts, MED11 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MED11 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher MED11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MED11 expression acts as an unfavorable survival marker.

SARC are the cancer types where MED11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.022	0.861	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

MED11–SARC (OS)

Open the SARC breakdown →